J&J: Still Kicking, Surprisingly

J&J (JNJ 0.02%), the company, is a bit like that slightly eccentric neighbor who’s been meticulously tending their garden for decades. You might not understand why they’re so obsessed with petunias, but you have to admire the dedication. They’re approaching a milestone – $100 billion in annual sales. It feels…significant. Not in a world-altering way, but in a “they’ve managed to avoid complete disaster for another year” kind of way. Only one other biopharma company has hit that mark, and that was Pfizer, riding the wave of pandemic panic. J&J’s doing it the old-fashioned way: slowly, steadily, and with a portfolio diverse enough to make a venture capitalist weep.







